184 related articles for article (PubMed ID: 15505625)
1. Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma.
Waters JS; Moss C; Pyle L; James M; Hackett S; A'hern R; Gore M; Eisen T
Br J Cancer; 2004 Nov; 91(10):1763-8. PubMed ID: 15505625
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents.
Tannir NM; Thall PF; Ng CS; Wang X; Wooten L; Siefker-Radtke A; Mathew P; Pagliaro L; Wood C; Jonasch E
J Urol; 2008 Sep; 180(3):867-72; discussion 872. PubMed ID: 18635226
[TBL] [Abstract][Full Text] [Related]
3. Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).
Bellmunt J; Trigo JM; Calvo E; Carles J; Pérez-Gracia JL; Rubió J; Virizuela JA; López R; Lázaro M; Albanell J
Lancet Oncol; 2010 Apr; 11(4):350-7. PubMed ID: 20163987
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008.
Stadler WM; Halabi S; Rini B; Ernstoff MS; Davila E; Picus J; Barrier R; Small EJ;
Cancer; 2006 Sep; 107(6):1273-9. PubMed ID: 16909426
[TBL] [Abstract][Full Text] [Related]
5. A phase ii study of gemcitabine and capecitabine in patients with advanced renal cell cancer: Southwest Oncology Group Study S0312.
Van Veldhuizen PJ; Hussey M; Lara PN; Mack PC; Gandour-Edwards R; Clark JI; Lange MK; Crawford DE
Am J Clin Oncol; 2009 Oct; 32(5):453-9. PubMed ID: 19487915
[TBL] [Abstract][Full Text] [Related]
6. A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma.
Rini BI; Weinberg V; Small EJ
Cancer; 2005 Feb; 103(3):553-8. PubMed ID: 15612026
[TBL] [Abstract][Full Text] [Related]
7. A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma.
Amato RJ; Khan M
Cancer Chemother Pharmacol; 2008 May; 61(6):1069-73. PubMed ID: 17701037
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy with capecitabine and interferon alfa-2A in patients with advanced renal cell carcinoma: a phase II study.
Padrik P; Leppik K; Arak A
Urol Oncol; 2004; 22(5):387-92. PubMed ID: 15464918
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma.
Bellmunt J; Suarez C; Gallardo E; Rodon J; Pons F; Bonfill T; Beltran M; Moya I; Galtes S; Albanell J; Carles J
Oncologist; 2014 Sep; 19(9):917-8. PubMed ID: 25142843
[TBL] [Abstract][Full Text] [Related]
10. A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.
Tagawa ST; Milowsky MI; Jeske S; Mazumdar M; Kung S; Sung M; Lehrer D; Matulich D; Selzer J; Wright JJ; Nanus DM
Am J Clin Oncol; 2011 Oct; 34(5):443-8. PubMed ID: 20881475
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma.
Cho JY; Paik YH; Chang YS; Lee SJ; Lee DK; Song SY; Chung JB; Park MS; Yu JS; Yoon DS
Cancer; 2005 Dec; 104(12):2753-8. PubMed ID: 16294346
[TBL] [Abstract][Full Text] [Related]
12. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
[TBL] [Abstract][Full Text] [Related]
13. A phase-II study of combination of pegylated interferon alfa-2a and capecitabine in locally advanced or metastatic renal cell cancer.
Sunela KL; Koskinen S; Kellokumpu-Lehtinen PL
Cancer Chemother Pharmacol; 2010 May; 66(1):59-67. PubMed ID: 19771431
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer.
Rini BI; Vogelzang NJ; Dumas MC; Wade JL; Taber DA; Stadler WM
J Clin Oncol; 2000 Jun; 18(12):2419-26. PubMed ID: 10856102
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal carcinoma.
Chung EK; Posadas EM; Kasza K; Karrison T; Manchen E; Hahn OM; Stadler WM
Am J Clin Oncol; 2011 Apr; 34(2):150-4. PubMed ID: 20395787
[TBL] [Abstract][Full Text] [Related]
16. Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre.
Jonasch E; Lal LS; Atkinson BJ; Byfield SD; Miller LA; Pagliaro LC; Feng C; Tannir NM
BJU Int; 2011 Mar; 107(5):741-747. PubMed ID: 21355978
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxic chemotherapy for metastatic renal cell carcinoma.
Stadler WM
Urologe A; 2004 Sep; 43 Suppl 3():S145-6. PubMed ID: 15164180
[No Abstract] [Full Text] [Related]
18. Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane.
Park JS; Jeung HC; Rha SY; Ahn JB; Kang B; Chon HJ; Hong MH; Lim S; Yang WI; Nam CM; Chung HC
Cancer Chemother Pharmacol; 2014 Oct; 74(4):799-808. PubMed ID: 25107569
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of weekly intravenous gemcitabine administration with interferon and interleukin-2 immunotherapy for metastatic renal cell cancer.
Neri B; Doni L; Gemelli MT; Fulignati C; Turrini M; Di Cello V; Dominici A; Maleci M; Mottola A; Ponchietti R; Raugei A; Valsuani G; Cini G
J Urol; 2002 Sep; 168(3):956-8. PubMed ID: 12187198
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of capecitabine and weekly docetaxel in metastatic renal cell carcinoma.
Marur S; Eliason J; Heilbrun LK; Dickow B; Smith DW; Baranowski K; Alhasan S; Vaishampayan U
Urology; 2008 Oct; 72(4):898-902. PubMed ID: 18692873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]